Cytek Biosciences, Inc. (CTKB) SEC Filings & Earnings Calls

Potential liability of $56.11M if verdict stands; ongoing litigation costs and possible injunctive relief risk.

“Jury awarded $20M lost profits and $36.11M royalties; company plans to challenge but outcome uncertain.”

Net loss widened YoY despite revenue growth; operating expenses growing faster than revenue.

“Net loss $12.2M vs $5.6M YoY; operating expenses +15% vs revenue +6%”

One-time tariff refund boosted gross margins; underlying margins lower (53% GAAP, 56% adjusted ex-refund).

“Excluding the impact of a one-time tariff refund, GAAP and adjusted gross margin in the second quarter of 2026 were 53% and 56%, respectively.” · word for word

Patent litigation with Beckman Coulter

“A trial is scheduled for August 17, 2026.” · word for word

Export controls on flow cytometers to China

“On January 15, 2025, the U.S. government announced new license requirements that impact exports of certain products and technology, including high-parameter and spectral flow cytometers and cell sorters...to certain countries, including China, which may have a significant negative impact on our sales, manufacturing and research and development activities.” · word for word

NIH funding uncertainty

“changes in the U.S. National Institutes of Health ("NIH") policy with respect to grants for academic research have impacted and may continue to impact our revenue from academic and government customers in the near term.” · word for word

Tariff and trade policy uncertainty

“the U.S. government's imposition of tariffs as well as threatened and actual retaliatory tariffs against U.S. goods may have a negative impact on our revenue and costs in the future.” · word for word

Key personnel departure risk: loss of Chief Legal Officer, though transition support in place.

“Valerie Barnett’s position as Chief Legal Officer and Corporate Secretary ... terminated on June 29, 2026.” · word for word

Potential sales execution risk due to departure of senior sales leader.

“resignation... to pursue another career opportunity”

Widening net loss and negative operating cash flow

“Net loss $ (18,866 ) $ (11,402 ); Net cash (used in) operating activities $ (2,736 ) $ (125 )” · word for word

Significant increase in G&A expenses

“General and administrative $18,467 $12,898”

Legal settlement liability

“Legal settlement liability, current $2,208; Legal settlement liability, noncurrent $6,637”

Litigation and consulting expenses driving G&A up 43% YoY, contributing to wider net loss.

“General and administrative expenses were $18.5 million for the first quarter of 2026, increasing 43% compared to the first quarter of 2025 due primarily to litigation-related expenses, outside consulting expenses and bad debt reserves.” · word for word

Gross margin slightly declining, indicating potential pricing or mix pressure.

“GAAP gross profit margin was 48% in the first quarter of 2026 compared to 49% in the first quarter of 2025.” · word for word

Material Weakness Remediation Completed

“the material weaknesses were remediated and management determined that we maintained effective internal control over financial reporting as of December 31, 2025” · word for word

Net Loss in 2025

“Net Income (in thousands) 2025: ($66,539)”

Underperformance vs Peer TSR

“Total Shareholder Return 2025: $26.92; Peer Group Total Shareholder Return 2025: $113.99”

Deferred tax asset valuation allowance of $38.1M indicates uncertainty in future profitability.

“Net loss in the fourth quarter of 2025 is primarily due to the recording of a non-cash valuation allowance against deferred tax assets of $38.1 million due to the uncertainty of realizing the associated future tax benefits.” · word for word

Operating expenses increased 25.5% in Q4, driven by litigation and G&A costs, outpacing revenue growth.

“Operating expenses were $38.5 million for the fourth quarter of 2025, an increase of $7.8 million or 25.5% compared to the fourth quarter of 2024 due to increased general and administrative and sales and marketing expenses.” · word for word

Gross margin compression due to product mix and cost pressures.

“GAAP gross profit margin was 53% in the fourth quarter of 2025 compared to 59% in the fourth quarter of 2024.” · word for word

Preliminary results subject to audit; actual results may differ.

“The preliminary financial results in this press release are not a comprehensive statement of Cytek’s financial results ... and have not been audited, reviewed or compiled by its independent registered public accounting firm.” · word for word

Export controls, tariffs, and NIH funding policies could impact future results.

“risks and uncertainties relating to global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business” · word for word

Export Control Risk

“In addition, the new license and export controls announced by the U.S. government in January 2025 that impact exports of certain products and technology, including high-parameter and spectral flow cytometers and cell sorters and certain mass spectrometry equipment to certain countries, including China, may have a negative impact on our sales, manufacturing a” · word for word

Tariff Cost Risk

“The lower product gross margins in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 were driven primarily by lower product revenue resulting in lower fixed cost absorption, higher overhead associated with a manufacturing site transition and increased tariff costs.” · word for word

Demand Slowdown Risk

“Certain of our pharmaceutical and biotech customers based in the United States have been impacted by the difficult fundraising environment for small companies and generally high interest rates. We believe these factors contributed to longer sales cycles, which adversely impacted our operating results for the three months ended September 30, 2025, and may adv” · word for word

NIH Funding Risk

“changes in the U.S. National Institutes of Health ("NIH") policy with respect to grants for academic research, specifically, the reduction in indirect cost reimbursement, has impacted and may continue to impact our revenue from academic and government customers in the near term.” · word for word

Internal Control Weakness

“We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or re” · word for word